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Background & objectives: In India, phase-I human clinical trials for a preventive HIV vaccine are
being conducted at Pune and Chennai Centres. In order to find out the willingness of populations
at risk to participate in future preventive HIV vaccine trials (HIVVTs) and to assess the factors
that enhance or deter them from  participation, a study was conducted at Chennai and Madurai in
Tamil Nadu.
Methods: This cross-sectional study was conducted among transport workers, people attending
sexually transmitted infection clinics, injection drug users, men having sex with men, women in
sex industry and a representative sample of monogamous married women, by employing
measurement scales. A structured questionnaire on knowledge and attitudes about the HIV vaccine
was used to measure the participants’ knowledge and attitudes about HIV vaccine and HIVVTs.
Results: Of the 112 participants, 67 (60%) were men. Mean age of the respondents was 32 yr;
68 per cent were high school educated. Majority of respondents were willing to participate in a
future HIVVT and the reasons were altruism, protection from HIV, and support for the researchers.
Major concerns were vaccine efficacy, side effects of the vaccine and the impact of a HIV vaccine
on the participants’ lives. Majority (85%) agreed that sex without condom would not be safe despite
the availability of an HIV vaccine.
Interpretation & conclusion: It is likely that high-risk volunteers will be willing to enroll in HIVVTs.
Barriers and concerns should be dealt with carefully by providing correct information. Also there
is a need for more education to ensure participants’ understanding of key concepts of HIV vaccine
trial.
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India has more than 5 million people living with
HIV/AIDS, the world’s second highest number of
infections after South Africa; thus representing a high
public health burden. Almost one-fourth of India’s
AIDS cases are among children and young people
below 25 yr of age. According to the National AIDS
Control Organisation(NACO), 68 new cases of HIV
occur every hour1. As the HIV epidemic has been
spreading from high to low risk populations and from
urban to rural areas over the last decade1,2-6, HIV
vaccine offers the best long-term hope to control the
AIDS epidemic.
Efforts to develop an HIV vaccine are being co-
ordinated by the Indian Council of Medical Research
(ICMR), NACO and the Department of
Biotechnology in India and their partner, the
International AIDS Vaccine Initiative (IAVI)2. The
first phase I trial of an HIV candidate vaccine was
conducted in the United States in 19877. Phase I trials
provide initial safety and immunogenicity data and
are conducted among small numbers of healthy
volunteers(30-50). Phase II trials provide information
on additional safety and immunogenicity in different
populations usually among hundreds of volunteers.
Phase III trials are designed as large scale, double-
blinded, controlled trials including thousands of
volunteers and conducted to assess the efficacy of
the candidate vaccine in preventing HIV infection
or disease8.
Currently, preparations for phase-I HIV vaccine
trials in India are underway. In 2002, a multiple HIV
vaccine candidate strategy approach was adopted and
two centers of excellence for the HIV vaccine clinical
and laboratory evaluation were set up at two ICMR
institutes at Pune and Chennai. India started its first
phase-I human clinical trial for a preventive HIV
vaccine with the Adeno-Associated Virus (AAV) in
February 2005 at the National AIDS Research
Institute (NARI) at Pune. The second phase-I trial is
being conducted at Tuberculosis Research Centre
(TRC) at Chennai, with Modified Vaccine Ankara
(MVA).
Clearly, HIV vaccines need to be delivered as a
part of an overall HIV prevention strategy, as initial
vaccines will be far from fully effective. Prior to any
vaccine trial, it is important to assess the concerns
of and perceptions about barriers and facilitators of
the community who might be participating in a future
HIV vaccine trial (HIVVT). Currently, little is known
about the challenges the community of participants
may experience as a result of engagement in a
HIVVT. Researchers preparing to initiate these trials
need to be adequately informed of the issues raised
by highly vulnerable groups who may already feel
stigmatized in the community. Therefore a
sociological study was conducted to investigate HIV
vaccine readiness among the high-risk groups in
Tamil Nadu for future HIV vaccine trials.
This study assessed factors that might impact the
decision of future participants to enroll in a HIVVT.
These individuals include subgroups who typically
engage in high risk activities, such as injection drug
users (IDUs), those engaged in unprotected sexual
activity with multiple partners, such as men having
sex with men (MSM), women working in the sex
industry, transport workers and those who report a
recent sexually transmitted infection (STI). Further,
as there are indications that HIV epidemic has moved
into the general population and the number of women
infected is steadily rising, a representative sample
of monogamous married women has also been
included for the study. The specific objectives of the
study were to assess the knowledge and attitude
towards HIVVT participation among groups at risk
for HIV as it relates to (i) willingness to participate
in a future HIVVT; (ii) factors that enhance or deter
these individuals from participating in a future
HIVVT; and (iii) the potential impact of HIVVT
participation on risky drug and sexual behaviour
among these persons.
Material & Methods
Design: A two-phased qualitative-quantitative design
was employed in collaboration with the UCLA
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Schools of Nursing and Medicine, USA. The original
study was a mixed method design in which
participants first completed focus group discussions
and then assisted in piloting several instruments
which have been previously modified in a culturally
sensitive manner by the community advisory board
(CAB). Structured scales were administered to the
participants at the end of the phase I qualitative study
during October 2004 to January 2005 in which focus
group discussions were conducted. These structured
scales, Knowledge of HIV/AIDS Vaccines Scale9 and
the Centers for Disease Control HIV Vaccine
Attitude Scale10 enabled the researchers to assess the
targeted community’ s current state of knowledge and
attitude towards participation in HIVVTs.
Participants and setting: The study population
consisted of several subgroups that were considered
at higher risk for HIV as compared with the general
population. These subgroups included transport
workers (TWs) such as truck drivers and cleaners,
persons diagnosed with a recent STI at Government
Hospital, IDUs; MSMs, and women in commercial
sex work (CSWs). In addition, a representative
sample of monogamous married women from the
self-help groups (SHGs) in the local communities
was included. The eligibility criteria for the study
were that the participants should be  above 15 yr and
willing to participate in the study. Besides, they
should be a member of the high-risk groups by
practicing high-risk behaviour except for married
women.
The study population was mainly drawn from 4
different non-governmental organizations (NGOs)
working in the field of HIV/AIDS at Chennai and
Madurai. They were the Association of Rural Mass
in India (ARM), Address Centre, Indian Community
Welfare Organization (ICWO), at Chennai and
Institute for Mass Awareness, Guidance and
Education (IMAGE) at Madurai.
Procedure: Prior to the onset of  the study, the study
protocols were extensively reviewed by CAB and
discussed and further modified in the Scientific
Advisory Committee Meeting and Institutional Ethics
Committee Meeting at the Tuberculosis Research
Centre (TRC), Chennai. After receiving the approval
of the Indian Council of Medical Research (ICMR),
NACO, the Institutional Review Board (IRB) of
UCLA, and the participant’s individual informed
consent, the focus groups were conducted in the local
language (Tamil) after screening. The research staff
consisting of the Indian investigators and their
facilitators underwent in special training on focus
group discussions (FGDs), data collection and data
analysis.
Participating NGOs informed their clients about
the study. Monogamous married women were
included from the local self-help groups (SHGs),
which were encouraged by the government
organizations for women empowerment. Interested
participants completed the initial consenting process
and completed a screener, which assessed that the
individual was a member of one of six selected groups
being assessed. Written informed consent was
obtained prior to data collection.
During pretesting, the researchers came to know
that the knowledge on HIVVTs was very minimal
among the study participants. Hence, at the opening
of the FGDs, participants were educated about the
meaning of a vaccine trial, particularly about the
double-blind selection of participants into the
vaccine or placebo groups, the possibility of testing
seropositive due to the production of antibodies
after taking a HIV vaccine, and the current
experimental status of the HIV vaccines. Care was
taken to inform the participants that there was no
HIV vaccine immediately available in India and that
the current study was a first step in assisting
researchers in preparation for a future trial. This
was followed by the FGDs in which questions were
asked on vaccines, facilitators or barriers to
participate and the impact of vaccination on risky
behaviour (findings not presented here). At the end
of the focus group interviews,  a socio-demographic
profile was completed along with other instruments
by interviewing each participant separately by the
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research staff to know his or her level of retention
on HIV vaccine concepts.   On the basis of
information available from this pilot study,
interview schedules were developed  to collect data
from a large sample. The participants were
compensated for spending their time, and travel
expenses and refreshments were provided after the
sessions.
The structured questions were precoded and
analyzed in SPSS 10.0 for windows (SPSS, Inc,
Chicago, IL, USA). Proportions, means with standard
deviations are used in appropriate places. Chronbach
alpha was used to test the reliability of the scales.
Socio-demographic information: Information was
collected regarding the date of birth, gender, religion,
education, employment status, income and the nature
of high-risk behaviour.
Knowledge of HIV/AIDS: Knowledge of HIV/AIDS
was assessed by an 11 item scale developed by Koblin
et al9. This scale measured the participant’s
knowledge on HIV vaccines and concepts about
participation in a HIVVT. The participants were
asked to respond ‘yes’ or ‘no’ for each item in the
scale. This scale had been previously tested in the
US and was further modified for the Indian
community after pretesting. Chronbach alpha was
0.5441.
HIV vaccine attitude: Attitudes about the HIV
vaccine was assessed by a 19 item HIV vaccine
attitude scale10 which reflects different beliefs or
attitudes towards HIVVTs. Subscale clustering
included trial protection, HIV altruism, trial
protection, tolerance for ambiguity and safer sex after
vaccination. For each statement, the study
participants were requested to respond as “disagree
strongly”, ‘disagree’, ‘undecided’, ‘agree’, ‘agree
strongly’, ‘refuse to answer’ and ‘don’t know’, which
will show how much they agree or disagree with each
statement. Chronbach alpha revealed 0.7096
regarding the reliability of the scale.
Results
Demographic profile: A total of 112 respondents
participated in the study of which 67 (60%) were
men. The subgroups included TWs (n = 20), MSMs
(n = 20), IDUs (n = 19), CSWs (n = 17), STI clinic
clients (n = 15) and married women (n = 21). The
mean age of the respondents was 32.4 ± 8.52 yr. More
Table I. Demographic and behavioural characteristics of trial
participants
Characteristics Male (n=67) Female (n=45)
No. (%) No. (%)
Focus group participants:
CSWs      - 17 (37.8)
IDUs 19 (28.4)      -
MSMs 20 (29.9)      -
STD attendees 8 (11.9) 7 (15.6)
Transport workers 20 (29.9)      -
Married women      - 21 (46.7)
Age (yr)*: 31.04 ± 7.86 34.24 ± 9.18
Education:
No formal education 13 (19.4) 15 (33.3)
School education 47 (70.1) 29 (64.5)
College/technical 7 (10.5) 1 (2.2)
Martial status:
Never married 41 (61.1) 1 (2.2)
Married 24 (35.8) 31 (68.9)
Separated/divorced/ 2 (2.9) 13 (28.9)
widowed
Religion:
Hinduism 58 (86.6) 32 (71.1)
Islam 4 (5.9) 2 (4.4)
Christianity 5 (7.5) 11 (24.5)
Nature of work:
Full time 43 (64.1) 20 (44.5)
Part time 16 (23.9) 2 (4.4)
Unemployed 2 (3) 5 (11.1)
Retired 1 (1.5) -
Others 5 (7.5) 18 (40)
CSWs, commercial sex workers; IDUs, injection drug users;
MSMs, men having sex with men
*Values are mean ± SD
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than half (68%) completed high school and 7 per cent
completed higher studies. Almost half of the sample
was married (42%); 38 per cent were single; 13 per
cent were separated/divorced/widowed. The samples
were primarily Hindus (81%) and employed full time
(56%) (Table I). Forty two per cent of the total
respondents perceived no risk of HIV/AIDS. Of the
remaining participants; 47 per cent reported
unprotected sex with multiple partners, 28 per cent
shared unclean needles, 9 per cent reported male-to-
male unprotected sex and 17 per cent reported other
risk behaviours.
Knowledge retained about HIVVT participation:
Findings of knowledge scale revealed that
approximately 90 per cent of the respondents answered
correctly regarding the safety of HIV vaccines, and
the ability of the vaccine to boost the body’s immunity.
These participants were also convinced that health care
would be provided for those experiencing vaccine-
related medical problems. These respondents were also
aware that some participants in a clinical trial would
receive the vaccine, while others would receive the
placebo. Knowledge about vaccine-induced HIV
positivity, the less than desired efficacy of early
vaccines, and the fallacy that the study nurse did not
decide the random assignment of the vaccine vs the
placebo ranged from 60-80 per cent. Fewer
respondents were aware that only HIV negative
participants  (as compared with both HIV positive and
HIV participants) were to be solicited in the future
HIVVT trials being planned, that they would receive
information about the substance they received (vaccine
or placebo), that one would not receive a guarantee
on participation in future HIVVTs, and the vaccine
might have an effect on their current negative HIV
antibody status.
Gender difference  was observed in relation to
the item on trial randomization and the difference
was statistically significant (P<0.05). For example,
82 per cent of the male respondents as compared to
100 per cent of female respondents were aware that
some participants would get the real vaccine and
some would get placebo (Table II).
HIV vaccine attitude scale: Three major domains
were identified: willingness to participate due to
altruism and other reasons, concerns and barriers for
Table II. Gender-wise distribution of responses of participants
understanding on HIV/AIDS vaccine trial concepts
Items Percentage of correct responses
Male=67 Female=45 Total=112
No. (%) No. (%) No. (%)
Healthcare for
vaccine-related 65 (97) 43 (96) 108 (96)
medical problems
Proven safety of
vaccines through 62 (93) 42 (93) 104 (93)
large scale HIVVTs
HIV vaccine
strengthens the 60 (90) 41 (91) 101 (90)
immune system
Some get the real
vaccine, and some 55* (82) 45 (100) 100 (89)
get a placebo
Post-vaccination
seropositivity due 46 (69) 26 (58) 72 (64)
to vaccine/infection
Study nurse will
select the 42 (63) 29 (64) 71 (63)
vaccine/placebo
Early vaccines -
not 100% 39 (58) 30 (67) 69 (62)
effective
Participants told
whether they got 34 (51) 31 (69) 65 (58)
the vaccine or placebo
People in these
studies will be in 34 (51) 31 (69) 65 (58)
future vaccine studies
No effect on 39 (58) 30 (67) 69 (56)
participant’s HIV
test results
Preventive trials
enroll both HIV+ 33 (49) 26 (58) 59 (53)
and HIV-
*P<0.05; compared to females
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participation, and future sexual behaviour change
after receiving an approved vaccine. The responses
did not show much variation between ‘disagree
strongly’and ‘disagree’ as well as between ‘agree’
and ‘agree strongly’, hence they were merged into
‘disagree’ and ‘agree’ for the purpose of analysis.
Benefits of participation in a future HIVVT: The
majority of participants voiced positive sentiments
about the future vaccine; in fact, 92 per cent revealed
the hope that there would be an effective vaccine in
a few years (Table III). A majority (93%) also
responded that their participation in a HIV vaccine
trial would reduce their chances of getting HIV
infection and hoped that the HIV vaccine would
protect them from HIV infection. Many believed that
HIV would be preventable similar to the polio
vaccine preventing polio.
A number of participants expressed altruism as
a rationale for their willingness to participate in a
future HIVVT. Almost all the participants (98%),
agreed that their participation in a HIVVT is
important for the common good of India.
Perceived barriers and concerns about HIVVT
participation: A total of 7 items covered concerns or
barriers participants perceived should they become
involved in a future HIVVT (Table IV). A majority
of concerns (61%) revolved around the unknown
efficacy of the vaccine, such as whether the vaccine
is powerful enough to prevent the HIV infection.
Additional concerns related to the effects of a HIV
vaccine on participant’s lives (50%), possible
unknown long-term side effects of the vaccine (32%),
and the impact of the vaccine on the participants’
ability to get insurance, marriage and job prospects
(31%). Less than 30 per cent of the responses worried
about whether they would be given the vaccine or
placebo (26%); 27 per cent were concerned about
restriction on travel due to participation in a HIVVT
(Table IV).
Table III. Gender-wise responses on personal and social benefits of HIV vaccine
Statements Agreed (%) Disagreed (%) Undecided (%) Don’t know (%)
M F M F M F M F
Personal benefits:
Less chance of getting infected 90 98 6 - 4 2 1 -
with HIV
Protection from HIV 92 89 3 9 5 2 - -
Social benefits:
There will be an effective HIV 90 96 6 - 3 2 1 2
vaccine in a few years
Vaccines will reduce the threat of. 93 93 6 5 1 - - 2
HIV infection
HIV will become preventable 87 96 4 2 6 - - 2
like polio
Willingness is important for the 97 100 2 - - - 1 -
common good of India
Help researchers prevent 97 96 3 4 - - - -
HIV/AIDS
Even if the vaccine does not work, 82 91 9 7 8 2 1 -
help researchers find an effective
vaccine
Number of participants = 112
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Sexual behaviour change after receiving a HIV
vaccine: The HIV vaccine scale also assessed
participants’ likelihood of sustained safe behaviour
subsequent to vaccination. The participants were
asked about their perception regarding possible risk
behaviour change if an actual HIV vaccine was
available, and whether behaviour would change
positively or negatively.
Overall, 85 per cent of respondents agreed that
sex without a condom would not be safe whether or
not there was a HIV vaccine available illustrating
the participants’ faith in condom use even after
receiving an approved vaccine. The response pattern
clearly emphasized the level of motivation prevalent
among each group on condom use. All MSMs (100%)
had agreed that condoms were necessary followed
by transport workers (95%), CSWs (94.1%), STIs
(86.7%), married women (76.2%) and IDUs (57.9%).
Approximately one-third of respondents agreed that
if they were to participate in a vaccine study, they
would have more faith in the vaccine to protect them
from HIV rather than safe sex. Similarly, about a third
agreed that an effective vaccine would make safe sex
less important and they would be less worried about
having unprotected sex.
Discussion
We attempted to assess the knowledge and
attitudes of targeted subgroups in a community in
Chennai and Madurai by sensitizing them through
focus groups discussions and obtaining the feedback
by using structured questionnaires. Findings revealed
that the overwhelming majority of participants were
willing to participate in a future HIVVT. In addition,
the majority of participants were confident about the
availability and safety of the vaccine and understood
basic mechanisms of action of the vaccine. This high
level of awareness of the vaccine was similar to that
a study conducted in Thailand11.
Majority (over 90%) of participants believed that
the HIV vaccine was the best hope for controlling
AIDS; these persons were also confident that such
vaccines could be produced. However, a major
concern across all study populations was the lack of
knowledge about which persons would be eligible to
enroll. For example, 47 per cent of the participants
believed that both HIV positive and HIV negative
people were appropriate for participation in HIVVTs,
despite the education on preventive vaccines. This
is also reported for a Ugandan cohort where they
conflate whether vaccines cure or prevent disease12,13.
Altruism was found to be a main motivation for
participating in efficacy trials across all study
populations. Overall, over 90 per cent of participants
indicated that their willingness to participate in an
Table IV. Concerns/barriers regarding trial participation
Statements Responses (%)
Agreed Disagreed Undecided Don’t know
Uncertanities-
uncomfortable 43 55 2
Unknown long-
term side 32 61 5 2
effects -
uncomfortable
Not willing
unless l knew 26 71 3
I was getting
the vaccine
Comfortable if
I knew the 61 35 3 1
vaccine is
powerful enough
Comfortable if
I knew how it 50 46 4 -
would affect
my life
Effect on
insurance, 31 53 6 10
marriage or
getting a job
Effect on 27 55 7 11
travel - uncomfortable
No of participants = 112
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HIVVTs was for the common good of India and for
the researchers to find an effective vaccine. In
addition, participants hoped that the vaccine would
be of personal benefit in terms of protection from
HIV infection. Similarly, in the study by Koblin
et al14 social benefit was rated most frequently as very
or somewhat important in the respondents’ decision-
making about participation in vaccine trial as
participation was based upon “helping to find a
vaccine that works”, followed closely by “helping
to stop the epidemic”. Almost 70 per cent of
volunteers from a cohort of high-risk homosexual
men in Rio de Janerio reported their willigness to
participate, with altruism being the main reason15,16.
In a study of a random household sample of 890
Kenyans from Nairobi and rural Thika7, findings
revealed that willingness increased with number of
sexual partners and level of education. The most
common reasons for refusing vaccinations were not
being at risk of HIV infection (47%), concern about
the safety of the vaccine (4%), and probability of
already being infected (3%). However, these findings
differed in other countries. In an Ugandan study,
88 per cent of military personnel reported willingness
to participate in trials7. Similarly in Pune, India, over
80 per cent of 349 patients attending sexually
transmitted disease clinics reported positive feelings
about the HIV vaccines in general; 48 per cent
reported willingness to participate in future HIV
vaccine trials17.
The most frequently rated concern or barrier
regarding the future HIVVT was vaccine efficacy and
safety. Another Ugandan study reported that the
desire to be protected from HIV/AIDS was a common
reason for being willing to participate in a
hypothecated vaccine trial and concern about side-
effects was a common reason for being unwilling18.
Majority (91%) believed participation in a HIVVT
would provide protection from HIV infection and
wanted an assurance that the vaccine would be
powerful enough to prevent the infection; they also
wanted to know about the consequences of
vaccination on their life.
In United States (US)-based studies conducted
with MSMs, findings revealed that willingness to
participate in trials declined from 37 per cent at
baseline to 21 per cent at 12 and 18 months when
participants were informed that they might receive a
portion of the HIV virus7. Vlahov et al19 found that
85 per cent IDUs initially expressed interest in
participating in a future HIVVT. However, interest
declined to 47 per cent when participants were
informed that the vaccine might result in a HIV
positive test. While research does indicate altruism
as a predominant factor in willingness20, persons who
perceived themselves to be at a greater risk, those
who received information about the greater per cent
efficacy of vaccine, and those who were given higher
incentives21 were more likely than their counterparts
to be willing to participate in HIVVTs.
To date, no studies have assessed the potential
impact of vaccine trial participation on continuation
of risky behaviour. Vlahov et al19 revealed that
37 per cent of IDUs would not maintain safe
behaviour and would rely on the vaccine for
protection. Similar intentions were prevalent among
military personnel in Uganda22, and in high-risk
women23. This information among future vaccine
participants in India is critical as ongoing
engagement in such activities could increase their
chances of becoming infected with the HIV virus.
One of the ethical concerns about the HIV
vaccine is the possible increase in the risky behaviour
or decreased use of condoms among vaccine
participants due to the notion of “chance” protection.
However, we found that our participants had more
faith on condoms than with on the HIV vaccine. This
attitude might be attributed to the priority given by
the government agencies and NGOs on regular
condom use for prevention of HIV infection.
This study had its own strengths and limitations.
The cross-sectional study was done  among different
types of high-risk populations and did not find any
significant difference in the responses of high-risk
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groups. But, it was interesting to note that women
were more willing to volunteer than men and the
reason quoted was the possible protection from HIV
infection from their husbands. Besides, CAB
comprising people from NGOs, PLWAs, medical
officers assisted the study team at all steps and this
process ensured that the phenomena of interest were
understood from the perspective of the clients
themselves. The small sample and one time
assessment of the participants willingness are the
study limitations. Further, the results of this study
may be limited in reasons of predicting actual
patterns of willingness once recruitment for a vaccine
efficacy trial begins. The hypothetical vaccine trial
presented did not refer to any specific vaccine
product of strategy and we do not know the actual
proportion of study population who might be willing
to participate once presented with a specific vaccine
product and trial. Another possible limitation of the
study was the structured nature of the measurement
scales, and hence, our inability to probe on negative
responses. Moreover, no baseline assessments were
done prior to the focus groups since the knowledge
about HIV vaccines and HIVVTs  was very minimal
and the participants were not able to understand and
answer the items in the scale without knowing the
vaccine concepts.
In conclusion, though majority of the study
participants with high-risk behaviours were willing
to participate in future HIV vaccine trials there is a
need for more education to ensure participants
understanding of key concepts. The information,
education and communication (IEC) materials for
HIV vaccine trials should focus on concepts such as
preventive vaccines, trial participants, double-
blinding, vaccine efficacy, safety and importance of
continuing safe sex behaviour among volunteers.
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